📈 Stocks · US

Eli Lilly and Stock LLY · Forecast & Analysis

Stocks US ISIN US5324571083
News situation · News, 30 days · no price data
▲ Bullish medium Data coverage good
Price no dataTrend no price dataNews ▲ 20 reports, latest 19.11.

Heads-up: USD Michigan Consumer Sentiment is due in 21 h (high impact). The outlook can shift noticeably around it.

Eli Lilly and Company (LLY) reads bullish on news flow: a Phase 3 win for oral GLP-1 Foundayo in sleep apnea, strong ObesityWeek data and a new consumer channel. With no chart signals, the view rests on fundamentals, tempered by Mounjaro lawsuits.

News situation · 20 items / 30 D
▲ Bullish medium Data coverage good
4.0 Impact / 10
By source type
Release 15 News 3 Filing 1 Earnings 1

17 of 20 straight from the issuer or regulator

AI-generated · as of November 16, 2026
News, 30 days
Bullish
Outlook

Outlook for Eli Lilly and Company

Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.

News picture · news of the last 30 days only
▲ Bullish medium
Data coverage good

No price statement: there is no price data for this asset. Based on 20 news items.

What drives it
  • Foundayo, Lilly's oral GLP-1, met its Phase 3 goal in sleep apnea, with an FDA filing planned by end of 2026
  • ObesityWeek presentations show strong weight-loss and sleep-apnea results for EloraTZP and retatrutide
  • Zepbound and Foundayo gain a direct-to-consumer channel via Hims & Hers, with self-pay pricing from $149 a month
  • Retatrutide Phase 3 trials showed large knee-pain reductions in osteoarthritis patients with obesity
What argues against it
  • Lawsuits allege NAION eye damage from Mounjaro, a safety challenge to a flagship GLP-1 medicine
  • The pipeline data come from investigational drugs that cannot yet be sold, so revenue stays distant
  • Financial terms of the Hims & Hers deal and the small Calytrix Bio acquisition were not quantified
What would change the picture
  • Whether Eli Lilly files the FDA submission for Foundayo in sleep apnea by the end of 2026
  • Any expansion of the NAION lawsuits or regulatory scrutiny of Mounjaro's safety
  • US retail sales and jobs data due shortly set only the macro backdrop for large American stocks
Coming up
  • US: Michigan Consumer Sentiment · expected 51.0, previous 51.0
  • US: CB Consumer Confidence Index · expected 91.5, previous 91.7
  • US: PCE price index, Jobless claims, GDP · expected 3.6%, previous 3.6%
All dates ↓ All times UTC.

Economic data for LLY

Full calendar

Recently released

  • TodayUSDPhiladelphia Fed Manufacturing Index●●●Forecast 32.2Previous 20.93 h ago
  • TodayUSDInitial Jobless Claims●●●3 h ago
  • November 18, 2026USDEIA Crude Oil Stocks Change●●●Actual 3.380MForecast -0.309MPrevious 4.657M25 h ago
  • November 17, 2026USDCore Retail Sales m/m●●●Actual 0.6%Forecast 0.7%Previous 1.1%worse than expected for USD2 days ago
  • November 17, 2026USDRetail Sales m/m●●●Actual 0.2%Forecast 0.3%Previous 0.8%worse than expected for USD2 days ago

Coming up

  • TomorrowUSDMichigan Consumer Sentiment●●●Forecast 51.0Previous 51.0in 21h
  • November 24, 2026USDCB Consumer Confidence Index●●●Forecast 91.5Previous 91.7in 4 days
  • November 25, 2026USDPCE Price Index y/y●●●Forecast 3.6%Previous 3.6%in 5 days
  • November 25, 2026USDPCE Price Index m/m●●●Forecast 0.4%Previous 0.5%in 5 days
  • November 25, 2026USDInitial Jobless Claims●●●in 5 days
  • November 25, 2026USDCore PCE Price Index y/y●●●Forecast 3.1%Previous 3.1%in 5 days
  • November 25, 2026USDCore PCE Price Index m/m●●●Forecast 0.3%Previous 0.3%in 5 days
  • November 25, 2026USDGDP Sales q/q●●●Forecast 1.7%Previous 1.7%in 5 days

All times UTC. Assessed against the consensus forecast, otherwise against the previous value.

Signal history

Both worlds over time

Technical and news signals of the last 30 days on one timeline.

Bullish ▲Bearish ▼24.10. · News signal · Impact 6/1025.10. · News signal · Impact 6/1026.10. · News signal · Impact 2/1027.10. · News signal · Impact 3/1028.10. · News signal · Impact 8/1028.10. · News signal · Impact 3/1029.10. · News signal · Impact 8/1029.10. · News signal · Impact 5/1030.10. · News signal · Impact 5/1002.11. · News signal · Impact 4/1004.11. · News signal · Impact 2/1005.11. · News signal · Impact 4/1005.11. · News signal · Impact 2/1009.11. · News signal · Impact 5/1011.11. · News signal · Impact 4/1012.11. · News signal · Impact 2/1014.11. · News signal · Impact 2/1014.11. · News signal · Impact 4/1016.11. · News signal · Impact 2/1019.11. · News signal · Impact 2/10
30 days ago today
Technical signal News signal Size = strength
News, 30 days

What is being reported about LLY

Release Neutral Impact 2/10
General Medicine Adds GLP-1 Weight Management Care to Eli Lilly's LillyDirect
General Medicine, a private healthcare store, announced its GLP-1 weight management care is now offered as an independent care option on LillyDirect, …
November 19, 2026
Release Neutral Impact 2/10
Eli Lilly to Acquire Calytrix Bio in Deal Valued at Up to $1.5 Billion
Lilly agreed to acquire Calytrix Bio, with shareholders receiving up to $1.5 billion in cash including upfront and milestone payments. The deal broade…
November 16, 2026
Release Bullish Impact 4/10
Eli Lilly Unveils New Clinical Data for Obesity Pipeline at ObesityWeek 2026
At ObesityWeek 2026 (November 14-17) Lilly presents quantified positive data: EloraTZP Phase 2 weight loss up to 23.3% and A1C reduction up to 2.9% at…
November 14, 2026
Release Bullish Impact 2/10
Innovent Biologics Adds 7 Drugs to China's 2026 National Reimbursement List
Eli Lilly licensed mazdutide (OXM3) to Innovent for China and also partners on sintilimab and licenses Jaypirca for Chinese commercialization. NRDL in…
November 14, 2026
Release Neutral Impact 2/10
Eli Lilly Breaks Ground on $3.5 Billion Pennsylvania Manufacturing Site
Lilly broke ground on a $3.5 billion Pennsylvania plant on Nov. 12, 2026 for injectable obesity medicines including retatrutide, within its previously…
November 12, 2026
News Bullish Impact 4/10
Nasdaq Rallies 4% This Week as Markets Navigate Chip Sector Volatility
Lilly is expanding distribution of Zepbound and Foundayo through the Hims & Hers platform with self-pay pricing from $149 to $299 per month, opening a…
November 11, 2026

Frequently asked questions about Eli Lilly and Company

What is the most important recent development for LLY?

Foundayo, the oral GLP-1 pill, met its primary endpoint in the Phase 3 ATTAIN-OSA trial, cutting sleep-apnea severity and body weight, with an FDA submission for that new use planned by end of 2026. The result was largely anticipated, but it would extend an already approved pill into a huge sleep-apnea market.

How serious are the Mounjaro lawsuits?

A law firm has filed multiple suits alleging eye-nerve damage (NAION) after Mounjaro use. That challenges the safety profile of a flagship GLP-1 medicine and can weigh on sentiment, but the filings are early, and any liability cost or regulatory consequence is not yet known.

What could change the bullish picture?

The clearest markers are the planned FDA filing for Foundayo in sleep apnea by end of 2026, any expansion of the NAION litigation, and, further out, approvals for the still-investigational retatrutide and EloraTZP. Conference data alone, however strong, do not yet add revenue.

Asset Snapshot

📝 Overview Generated automatically

LLY has been the subject of 73 signals across 73 articles in the last 365 days. Sentiment skews Bullish (45%).

Breakdown: 33 bullish, 7 bearish, 33 neutral.

Most-cited catalysts: Supreme Court denies appeal on $194 million Medicaid penalty (1×), Immediate earnings charge in upcoming quarter (1×), Validation of oral GLP-1 category by EMA (1×). Most-cited risk factors: Lilly's strong cash position may mitigate market reaction (1×), Ruling was expected and priced in (1×), Novo's oral Wegovy may establish strong brand loyalty before Lilly's launch (1×).

Keep exploring

Related assets

Same category or comparable signal picture — each card opens the full cockpit.